BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

888 related articles for article (PubMed ID: 17166343)

  • 1. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
    Peterson GE
    Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis.
    Monami M; Marchionni N; Mannucci E
    Diabetes Res Clin Pract; 2008 Aug; 81(2):184-9. PubMed ID: 18495286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus.
    Karges B; Muche R; Riegger I; Moritz M; Heinze E; Debatin KM; Wabitsch M; Karges W
    Clin Ther; 2006 Dec; 28(12):2094-101. PubMed ID: 17296465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
    Baxter MA
    Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin detemir (levemir), a new long-acting insulin.
    Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
    Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
    Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes.
    Päivärinta M; Tapanainen P; Veijola R
    Pediatr Diabetes; 2008 Jun; 9(3 Pt 2):83-90. PubMed ID: 18221431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initiation of insulin glargine in children and adolescents with type 1 diabetes.
    Tan CY; Wilson DM; Buckingham B
    Pediatr Diabetes; 2004 Jun; 5(2):80-6. PubMed ID: 15189493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
    Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
    Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin detemir: new drug. A second long-acting insulin analogue: many uncertainties, few advantages.
    Prescrire Int; 2006 Oct; 15(85):163-7. PubMed ID: 17121210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-acting insulin analogs: progressing slowly].
    Holleman F; Hoekstra JB
    Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1668-9. PubMed ID: 15453117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin glargine: a long-acting insulin for diabetes mellitus.
    Garces K
    Issues Emerg Health Technol; 2003 Nov; (52):1-4. PubMed ID: 14626260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic insulin analogs and their use in dogs and cats.
    Gilor C; Graves TK
    Vet Clin North Am Small Anim Pract; 2010 Mar; 40(2):297-307. PubMed ID: 20219490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basal insulins: Pharmacological properties and patient perspectives.
    Abrahamson MJ
    Prim Care Diabetes; 2010 Apr; 4 Suppl 1():S19-23. PubMed ID: 20394887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin detemir: a new basal insulin analogue.
    Soran H; Younis N
    Diabetes Obes Metab; 2006 Jan; 8(1):26-30. PubMed ID: 16367879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin preparations with prolonged effect.
    Owens DR
    Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S5-14. PubMed ID: 21668337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin analogs versus human insulin in type 2 diabetes.
    Migdalis IN
    Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S102-4. PubMed ID: 21864739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refining basal insulin therapy: what have we learned in the age of analogues?
    Devries JH; Nattrass M; Pieber TR
    Diabetes Metab Res Rev; 2007 Sep; 23(6):441-54. PubMed ID: 17668418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.
    Wutte A; Plank J; Bodenlenz M; Magnes C; Regittnig W; Sinner F; Rønn B; Zdravkovic M; Pieber TR
    Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.